BMO Capital Maintains Underperform Rating on Neurocrine Bio (NBIX), "Outlook for Ingrezza Has Not Changed"
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Underperform rating and $82.00 price target on Neurocrine Bio. (NASDAQ: NBIX), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
